Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
840 stopped studies mapped to Malignant Prostate Neoplasm and descendants · 92% state a reason
Over the 840 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04249947 | P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant… | Phase 1 | terminated | Jan 31, 2020 | Poseida Therapeutics, Inc. | Study closed | Other (stated, no rule matched) |
| NCT05241613 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 1 | terminated | Feb 16, 2022 | Accutar Biotechnology Inc | Subject benefit-risk ratio changes, sponsor decides to voluntarily terminate study | Other (stated, no rule matched) |
| NCT03862170 | Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer(BRP30) | Phase 3 | terminated | Mar 5, 2019 | CR-CSSS Champlain-Charles-Le Moyne | Covid-19 pandemic | COVID-19 / pandemic |
| NCT02608359 | A Post-marketing Surveillance to Assess Safety of Abiraterone Acetate (Zytiga) in Indian… | — | withdrawn | Nov 18, 2015 | Johnson & Johnson Private Limited | No subjects recruited in the study | Enrollment / accrual |
| NCT05123300 | PRISMA-PET - Primary Staging of Prostate Cancer With PSMA | N/A | terminated | Nov 17, 2021 | Odense University Hospital | Due to change of EAU guidelines, where PSMA-PET/CT is now recommended for primary staging of… | Other (stated, no rule matched) |
| NCT03465579 | Mp-3TMRI and 68Ga-PSMA PET/CT Guided Prostate Biopsy and Tumor Node Metastasis (TNM)…(BIOPSTAGE) | N/A | terminated | Mar 14, 2018 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Patients in cohort 1 continued for prolonged periods given the difficulties encountered in the… | COVID-19 / pandemic |
| NCT05501548 | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant… | Phase 2 | terminated | Aug 15, 2022 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study was terminated by the IRB due to low accrual, | Enrollment / accrual |
| NCT04134208 | An Investigational Scan (18F-Fluciclovine PET-CT) for the Measurement of Therapeutic… | Phase 4 | terminated | Oct 22, 2019 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05568537 | Prostate MRI and Pylarify PSMA PET/CT | Phase 4 | withdrawn | Oct 5, 2022 | Corewell Health East | Study withdrawn due to lack of funding and resources | Funding |
| NCT04951492 | Olaparib for the Treatment of Castration Resistant Prostate Adenocarcinoma | Phase 2 | terminated | Jul 6, 2021 | University of Washington | Withdrawal of funding | Funding |
| NCT05709535 | PSMA-PET/CT Registry | — | terminated | Feb 2, 2023 | AHS Cancer Control Alberta | Not due to a safety concern; terminated early due to changing clinical trial landscape at centre | Safety / toxicity |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT05917470 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate… | Phase 1 / Phase 2 | terminated | Jun 23, 2023 | Oncternal Therapeutics, Inc | Oncternal Therapeutics, Inc. announced on 12 SEP 2024 its decision to discontinue its clinical… | Other (stated, no rule matched) |
| NCT01350180 | Assessing DNA Changes in High Risk Prostate Cancer to Determine Prognosis | — | withdrawn | May 9, 2011 | Dr. Tamim Niazi | not stated | Not stated |
| NCT02588404 | The Predictive Value of TMPRSS2-ERG Fusion in High Risk Prostate Cancer Patient | — | withdrawn | Oct 27, 2015 | Sir Mortimer B. Davis - Jewish General Hospital | not stated | Not stated |
| NCT05826470 | Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of… | N/A | terminated | Apr 24, 2023 | Genesis Research LLC | Business decision of the Sponsor | Sponsor / business decision |
| NCT02588846 | Multi-target Tracking in Prostate Radiotherapy Using MLC and KIM(KOALA) | N/A | withdrawn | Oct 28, 2015 | Royal North Shore Hospital | no resources to run the trial | Other (stated, no rule matched) |
| NCT03990194 | Real-life Study of Patients After 3-months of Leuprorelin 5mg Implant in Prostate Cancer(LEPTO) | — | withdrawn | Jun 18, 2019 | RECORDATI GROUP | Internal decision | Other (stated, no rule matched) |
| NCT06218667 | A Study of Copanlisib in Combination with Degarelix in People with Prostate Cancer | Phase 1 / Phase 2 | withdrawn | Jan 23, 2024 | Memorial Sloan Kettering Cancer Center | Study drug not available per sponsor | Other (stated, no rule matched) |
| NCT06016504 | Adaptive Virtual Consultation Tool to Enhance Education and Understanding in Patients… | N/A | terminated | Aug 29, 2023 | Mayo Clinic | Low/slow accrual | Enrollment / accrual |
| NCT04291664 | PK and Dose Escalation and Expansion Study of DST-2970 | Phase 1 | terminated | Mar 2, 2020 | DisperSol Technologies, LLC | Dose escalation portion of the study completed, one expansion cohort was eliminated due to change… | Enrollment / accrual |
| NCT05156905 | Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate… | Phase 1 | terminated | Dec 14, 2021 | University of California, San Diego | Oncternal closing clinical trial operations. | Other (stated, no rule matched) |
| NCT04312191 | Using Meditation for Oncology Anxiety | N/A | withdrawn | Mar 18, 2020 | Mellar Davis MD | Study was not started and PI is retiring. | Other (stated, no rule matched) |
| NCT03177187 | Combination Study of AZD5069 and Enzalutamide.(ACE) | Phase 1 / Phase 2 | terminated | Jun 6, 2017 | Institute of Cancer Research, United Kingdom | Discontinuation of production of IMP | Other (stated, no rule matched) |
| NCT05707182 | 18F-rhPSMA-7.3 PET/MRI in Prostate Cancer Active Surveillance: a Pilot Study | Early Phase 1 | withdrawn | Jan 31, 2023 | University of Alabama at Birmingham | Recruitment was difficult. | Enrollment / accrual |
| NCT03459755 | Evaluating Race Specific AGE Accumulation As a Behavioral Biomarker Prostate Cancer… | N/A | withdrawn | Mar 9, 2018 | Medical University of South Carolina | investigator decision | Investigator |
| NCT03777982 | Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate +… | Phase 3 | terminated | Dec 19, 2018 | Dana-Farber Cancer Institute | PI is terminating the study due to slow/low accrual | Enrollment / accrual |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
| NCT05929300 | A Yoga Program for Patients Undergoing Prostate Cancer Surgery | N/A | withdrawn | Jul 3, 2023 | VA Office of Research and Development | Lack of recruitment | Enrollment / accrual |
| NCT06329830 | 177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer(LUNAAR) | Phase 1 / Phase 2 | withdrawn | Mar 26, 2024 | Baptist Health South Florida | Funding for the study was withdrawn. | Funding |
| NCT00773773 | Combination of Serum Measurements of Molecular Biomarkers and Serum Protein Profiling Can… | N/A | terminated | Oct 16, 2008 | Memorial Sloan Kettering Cancer Center | Protocol closed to accrual early due to PI retirement. | Enrollment / accrual |
| NCT00321698 | Radiation Therapy and Docetaxel in Treating Patients Who Are Undergoing Surgery for… | Phase 1 / Phase 2 | terminated | May 4, 2006 | OHSU Knight Cancer Institute | Funding withdrawal | Funding |
| NCT03056638 | Trial of ADT and SBRT Versus SBRT for Intermediate Prostate Cancer | Phase 3 | terminated | Feb 17, 2017 | Memorial Sloan Kettering Cancer Center | Due to low accrual | Enrollment / accrual |
| NCT03850795 | HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 3 | terminated | Feb 22, 2019 | Hinova Pharmaceuticals USA, Inc. | Terminated by Sponsor for various factors including prolonged duration and enrollment challenges | Enrollment / accrual |
| NCT06065059 | Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant… | Phase 1 / Phase 2 | terminated | Oct 3, 2023 | Tango Therapeutics, Inc. | Terminated due to safety | Safety / toxicity |
| NCT05084859 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally… | Phase 1 | terminated | Oct 20, 2021 | Biosplice Therapeutics, Inc. | Study was terminated due business reasons by Sponsor. | Sponsor / business decision |
| NCT05415696 | Prostatic Artery Embolization for the Treatment of Lower Urinary Tract Symptoms in… | N/A | withdrawn | Jun 13, 2022 | Stanford University | Enrolling to this clinical trial was too difficult | Enrollment / accrual |
| NCT00848601 | Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and… | Phase 1 | terminated | Feb 20, 2009 | Astex Pharmaceuticals, Inc. | The dose limiting toxicity of cardiac QTc prolongation was identifiedin the phase 1 study in… | Safety / toxicity |
| NCT04629781 | Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in… | Phase 1 | terminated | Nov 16, 2020 | Swiss Cancer Institute | SAKK decided to premature terminate this trial as additional follow-up visits do not further… | Efficacy / futility |
| NCT04293406 | pCHIP: Prostate Cancer Health Impact Program | — | terminated | Mar 3, 2020 | Weill Medical College of Cornell University | Study has been stopped due to lack of follow up questionnaires being completed. | Other (stated, no rule matched) |
| NCT03134027 | Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of…(Immune PDX) | — | terminated | Apr 28, 2017 | Duke University | Poor accrual | Enrollment / accrual |
| NCT04159896 | ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer | Phase 2 | terminated | Nov 12, 2019 | Barbara Ann Karmanos Cancer Institute | The study was closed to accrual on 3/1/21 due to safety concerns since 2 patients experienced CVA… | Safety / toxicity |
| NCT03770455 | Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC | Phase 2 | terminated | Dec 10, 2018 | Jodi Layton, MD | Early signs of progression and learned experience that the assumed time period between psa… | Other (stated, no rule matched) |
| NCT03690141 | An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced… | Phase 2 | terminated | Oct 1, 2018 | Effector Therapeutics | Terminated early due to a lack of efficacy. | Efficacy / futility |
| NCT03632655 | A Prospective, Randomized Trial Comparing Office-based MR-guided Prostate Biopsy… | N/A | terminated | Aug 15, 2018 | Weill Medical College of Cornell University | The study was terminated due to procurement of new funding sources. | Funding |
| NCT01794936 | Pilot Study of VTI Doppler Probe Use to Identify Neurovascular Bundle During Prostate… | N/A | terminated | Feb 20, 2013 | Columbia University | PI left the institution | Investigator |
| NCT03458234 | RAD 1801: Pilot Study of Intra-Urethral Radiotransponder Beacon Guided Focal Prostate…(RAD1801) | N/A | terminated | Mar 8, 2018 | University of Alabama at Birmingham | No longer manufacturing radiotransponder beacons. No similar product available. The results are no… | Drug supply |
| NCT04726332 | Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors… | Phase 1 | terminated | Jan 27, 2021 | Exelixis | Business reasons | Sponsor / business decision |
| NCT03035357 | Neoadjuvant Listeria or Daratumumab in Prostate Cancer | Phase 2 | withdrawn | Jan 30, 2017 | M.D. Anderson Cancer Center | PI's Request | Other (stated, no rule matched) |
| NCT04684628 | 68Ga-PSMA PET/CT in Prostate Cancer | Phase 3 | suspended | Dec 24, 2020 | University of Saskatchewan | Study is suspended due to some logistic issues | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Feb 17, 2025source: clinicaltrials